Bridging The Gap: Satisfying Payers In An Era of Expedited Regulatory Pathways

August 23, 2017

Regulatory approval has always been the main hurdle for developers trying to bring needed new drugs to patients. However, today, as expedited regulatory pathways enable drugs for severe diseases to be approved with less data, the gap has widened between what evidence regulators require and what payers desire to make their reimbursement decisions. Companies need to bridge the gap to ensure approvals are obtained from both regulators and payers so patients can get the treatments they need.

Previous Flipbook
Nothing Costs More Than Failure
Nothing Costs More Than Failure

Learn the top reasons drugs fail to be recommended for market access.

Next Flipbook
Five Ways to Ensure Your Early Engagement with Payers and Regulators Pays Off
Five Ways to Ensure Your Early Engagement with Payers and Regulators Pays Off

Early Engagement is Smart but You Need to be Savvy when Engaging with Regulators and Payers.

×

Speak to a Parexel® Biotech expert today!

First Name
Last Name
Job Title
Company Name
Country
Tell us how we can help
Thank you!
Error - something went wrong!